Tune Therapeutics
Dr. Charles A. Gersbach is the Acting Chief Scientific Officer and Co-Founder of Tune Therapeutics.
A renowned academic and genome engineer, Charlie is the John W. Strohbehn Distinguished Professor of Biomedical Engineering at Duke University, and Director of the Duke Center for Advanced Genomic Technologies.
His research is focused on genome and epigenome editing, cellular engineering, gene therapy, synthetic biology, and regenerative medicine. His work has led to entirely new approaches to programming cell biology and the treatment of genetic disease and has earned him numerous awards, along with induction as a Fellow of the American Institute for Medical and Biological Engineering. He is also the co-founder of three biotechnology companies and an advisor to several others.
He received his Ph.D. in Biomedical Engineering from the Georgia Institute of Technology and Emory University and completed postdoctoral training at The Scripps Research Institute.
Tune Therapeutics
1 followers
With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine. With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.